Clinical Trial Update: An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

View source ↗

Summary

An open-label, multi-center expanded access program evaluating eribulin in advanced/metastatic breast cancer refractory to prior therapy. The document notes eri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)

Snippet

Sponsor: Eisai Inc. | Conditions: Metastatic Breast Cancer | Status: APPROVED_FOR_MARKETING